Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
CUV Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$9.76 - AU$17.71
Previous CloseN/A
Volume193.84K
Average Volume (3M)66.89K
Market Cap
$516.27M
Enterprise ValueN/A
Total Cash (Recent Filing)$198.22M
Total Debt (Recent Filing)AU$715.38K
Price to Earnings (P/E)13.3
Beta0.39
Next Earnings
Sep 02, 2025EPS Estimate
0.38Last Dividend Ex-Date
Sep 05, 2024Dividend Yield0.45%
Share Statistics
EPS (TTM)0.28
Shares Outstanding50,123,630
10 Day Avg. Volume81,736
30 Day Avg. Volume66,895
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.62
Price to Sales (P/S)0.00
P/FCF Ratio24.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.32Price Target Upside281.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Clinuvel Pharmaceuticals News
PremiumCompany Announcements
Clinuvel Advances Vitiligo Treatment with SCENESSE®
PremiumCompany Announcements
CLINUVEL Showcases SCENESSE® Efficacy at EADV Symposium
PremiumCompany Announcements
JPMorgan Chase & Co. Ceases Substantial Holding in Clinuvel Pharmaceuticals
PremiumCompany Announcements
Clinuvel Completes Recruitment for Phase III Vitiligo Trial
PremiumCompany Announcements
Clinuvel Pharmaceuticals Ceases 19,000 Performance Rights
PremiumCompany Announcements
CLINUVEL PHARMACEUTICALS Issues New Shares to Bolster Market Position
PremiumCompany Announcements
Clinuvel Pharmaceuticals Issues Shares Under Incentive ProgramOptions Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
2.73%
Mutual Funds
― Other Institutional Investors
95.67% Public Companies and
Individual Investors
CUV FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest share price was AU$9.76 and its highest was AU$17.71 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Clinuvel Pharmaceuticals Limited’s market cap is $516.27M.
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 02, 2025 which is in 82 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 26, 2025. The company reported AU$0.28 earnings per share for the quarter, beating the consensus estimate of AU$0.217 by AU$0.063.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.45%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.38.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,123,630 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.28 in its last earnings report, beating expectations of AU$0.217. Following the earnings report the stock price went up 2.89%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:CUV
Clinuvel Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.32 (281.73% Upside)
$39.32 (281.73% Upside)
Blogger Sentiment
Bullish
AU:CUV Sentiment 90%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.20%
12-Months-Change
Fundamentals
Return on Equity
19.93%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company focused on developing and delivering innovative treatments for patients with unmet medical needs, primarily in the field of photoprotection and skin disorders. The company's core product, SCENESSE®, is designed to treat erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxic reactions to sunlight. Clinuvel operates within the pharmaceutical and biotechnology sectors, leveraging its expertise in dermatology to expand its product pipeline and address other skin-related conditions.
CUV Company Deck
CUV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and operational successes, such as expansion in treatment networks and ongoing development in the vitiligo program. However, rising expenses and challenges in drug development and regulatory approvals present some concerns. Despite these challenges, the company remains optimistic about future growth and market recognition.Read More>Technical Analysis
Opthea
―
PYC Therapeutics Limited
―
Clarity Pharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―